Intercept Pharmaceuticals
Financials
Estimates*
| USD | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Revenues | 252m | 313m | 363m | 286m | 331m | 361m | 361m |
| % growth | 40 % | 24 % | 16 % | (21 %) | 16 % | 9 % | - |
| EBITDA | (304m) | (212m) | (53.6m) | (61.7m) | (41.5m) | 78.6m | (7.8m) |
| % EBITDA margin | (120 %) | (68 %) | (15 %) | (22 %) | (13 %) | 22 % | (2 %) |
| Profit | (345m) | (275m) | (91.4m) | 222m | (52.7m) | 97.0m | 85.1m |
| % profit margin | (137 %) | (88 %) | (25 %) | 78 % | (16 %) | 27 % | 24 % |
| EV / revenue | 15.6x | 2.9x | 1.6x | 0.9x | 2.1x | 1.5x | 1.3x |
| EV / EBITDA | -13.0x | -4.3x | -11.0x | -4.0x | -16.6x | 7.1x | -58.1x |
| R&D budget | 243m | 191m | 185m | 177m | - | - | - |
| R&D % of revenue | 96 % | 61 % | 51 % | 62 % | - | - | - |
Source: Dealroom estimates
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | N/A | - | |
$25.0m | Series A | ||
$25.0m | Series B | ||
$30.0m | Series C | ||
| N/A | $75.0m | IPO | |
| N/A | $61.7m | Post IPO Equity | |
| N/A | $338m | Post IPO Equity | |
* | N/A | $448m | Post IPO Debt |
$250m | Post IPO Equity | ||
* | N/A | Acquisition | |
| Total Funding | €72.7m | ||
Related Content
Recent News about Intercept Pharmaceuticals
EditIntercept Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to developing and commercializing innovative therapies for patients with progressive non-viral liver diseases. The company primarily serves healthcare providers and patients in the United States, European Union, Canada, Israel, Switzerland, Australia, Liechtenstein, and the United Arab Emirates. Operating in the biopharmaceutical market, Intercept focuses on addressing critical needs in liver health through its novel scientific platform.
The company's business model revolves around research and development, followed by the commercialization of its therapies. Intercept generates revenue through the sale of its flagship product, Ocaliva, which is used to treat primary biliary cholangitis (PBC), a chronic liver disease. The company also invests in ongoing clinical trials to expand its product pipeline and address additional liver diseases.
Intercept's mission is to build a healthier tomorrow for patients with progressive non-viral liver diseases. The company values collaboration, integrity, excellence, innovation, passion, and patient-centricity. Intercept is committed to safeguarding the health of its team and the patients it serves, especially in light of the COVID-19 pandemic.
Keywords: biopharmaceutical, liver diseases, Ocaliva, PBC, healthcare providers, innovative therapies, clinical trials, patient-centric, liver health, commercialization.